Intra-Cellular Therapies Inc (ITCI)
86.17
-0.37
(-0.43%)
USD |
NASDAQ |
Nov 04, 16:00
86.16
-0.01
(-0.01%)
After-Hours: 20:00
Intra-Cellular Therapies Revenue (Quarterly): 175.16M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 175.16M |
| June 30, 2024 | 161.28M |
| March 31, 2024 | 144.84M |
| December 31, 2023 | 131.51M |
| September 30, 2023 | 125.81M |
| June 30, 2023 | 110.13M |
| March 31, 2023 | 94.73M |
| December 31, 2022 | 87.43M |
| September 30, 2022 | 71.87M |
| June 30, 2022 | 55.07M |
| March 31, 2022 | 34.76M |
| December 31, 2021 | 25.52M |
| September 30, 2021 | 21.61M |
| June 30, 2021 | 19.01M |
| March 31, 2021 | 15.58M |
| December 31, 2020 | 12.40M |
| September 30, 2020 | 7.369M |
| June 30, 2020 | 1.876M |
| March 31, 2020 | 0.8825M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 |
| Date | Value |
|---|---|
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.0051M |
| September 30, 2017 | 0.0308M |
| June 30, 2017 | 0.1147M |
| March 31, 2017 | 0.0953M |
| December 31, 2016 | 0.0979M |
| September 30, 2016 | 0.0044M |
| June 30, 2016 | 0.2284M |
| March 31, 2016 | |
| December 31, 2015 | -0.03M |
| September 30, 2015 | |
| June 30, 2015 | 0.0574M |
| March 31, 2015 | 0.0033M |
| December 31, 2014 | 0.0361M |
| September 30, 2014 | 0.1244M |
| June 30, 2014 | 0.2192M |
| March 31, 2014 | 0.1678M |
| December 31, 2013 | 0.8275M |
| September 30, 2013 | 0.668M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.8825M
Minimum
Mar 2020
175.16M
Maximum
Sep 2024
68.25M
Average
55.07M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 241.96M |
| Ionis Pharmaceuticals Inc | 225.25M |
| Madrigal Pharmaceuticals Inc | 62.18M |
| AbbVie Inc | 14.46B |
| Arcus Biosciences Inc | 39.00M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -26.32M |
| Total Expenses (Quarterly) | 214.01M |
| EPS Diluted (Quarterly) | -0.25 |
| Enterprise Value | 8.129B |
| Gross Profit Margin (Quarterly) | 91.26% |
| Profit Margin (Quarterly) | -15.03% |
| Earnings Yield | -1.01% |
| Normalized Earnings Yield | -1.010 |